TABLE II.
Rates of major bleeding complications in patients with high-risk features in the HOKUSAI VTE Cancer trial7
| Risk factor | Major bleeding (%) | p Value | |
|---|---|---|---|
| Edoxaban | Dalteparin | ||
| Urothelial cancer | 13.2 | 0 | NA |
| Creatinine clearance 30–50 mL/min | 10.5 | 2.9 | NA |
| Platelets 50–100×103/mL | 12.5 | 4.3 | NA |
| Use of antiplatelet agents | 11.5 | 3.2 | NA |
| 3 Risk factorsa | 13.5 | 4.1 | <0.05 |
| 4 Or more risk factorsa | 10.5 | 4.2 | NA |
a
Defined as surgery within the preceding 2 weeks, use of antiplatelet agents, primary or metastatic brain tumour, regionally advanced or metastatic cancer, gastrointestinal or urothelial cancer diagnosed within the preceding 6 months, or treatment with bevacizumab within the preceding 6 weeks.
NA = not available.